Roche dumps fibrosis alliance with Belgian biotech

Swiss drug giant Roche ($RHHBY) has exited an alliance with Belgium-based biotech Galapagos that focused on fibrosis discovery, leaving Galapagos hunting for another partner to hunt for compounds against fibrotic diseases. On its way out, Roche is forking over €5.75 million to Galapagos for the biotech's efforts through 2012, increasing the total payments from the alliance to €16 million, according to the company. "We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, CEO of Galapagos, in a statement. Fibrotic diseases such as pulmonary fibrosis have been a hot area of drug development among biopharma players, including Biogen Idec ($BIIB), Bristol-Myers Squibb ($BMY) and Novartis ($NVS). There are no approved treatments for idiopathic pulmonary fibrosis in the U.S. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.